Resources Repository
-
GuidelinesPublication 2011HPV Vaccine Introduction in LMIC's: Guidance on the Use of Cost-Effectiveness Models
This article is a literature review of HPV vaccination models suitable for low-income and middle-income …
This article is a literature review of HPV vaccination models suitable for low-income and middle-income country use to provide information about the feasibility of using such models in a developing country setting. The authors evaluated models in terms of their capacity, requirements, limitations and comparability. Their literature review identified six HPV vaccination models suitable for low-income and middle-income country use and representative of the literature in terms of provenance and model structure. Each model was…
Calibration/Validation | Science/Technology | Chronic Disease/Risk | Clinical Care | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Global -
ReviewPublication 2011Simulation Models of Obesity: A Review of the Literature
Simulation models combine information from a variety of sources to provide a useful tool for …
Simulation models combine information from a variety of sources to provide a useful tool for examining how the effects of obesity unfold over time and impact population health. They can aid in the understanding of the complex interaction of the drivers of diet and activity and their relation to health outcomes. This paper provided an overview of different types of simulation models used to evaluate the potential impact of policies to address the obesity epidemic.…
Decision Analysis | Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Mathematical Models | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Food/Agriculture | Health/Medicine -
ArticlePublication 2009Cost Effectiveness Analysis of Including Boys in a HPV Vaccination Program in the U.S.
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a …
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a routine human papillomavirus (HPV) vaccination program for preadolescent girls. The analysis included girls and boys aged 12 years; interventions included HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer. The authors found that with 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12-year-old girls…
Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Clinical Care | Dynamic Transmission | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | North America -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Calibration/Validation | Economics/Finance | Science/Technology | Chronic Disease/Risk | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Asia & Pacific -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean
This article reports on a model-based approach estimated averted cervical cancer cases and deaths, disability-adjusted …
This article reports on a model-based approach estimated averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for human papillomavirus (HPV) vaccination of young adolescent girls using population and epidemiologic data for 33 countries in Latin America and the Caribbean (LAC). The authors found that an absolute reduction in lifetime cancer risk varied between countries, depending on incidence, proportion attributable to HPV-16 and 18, and population age-structure; for…
Calibration/Validation | Economics/Finance | Science/Technology | Chronic Disease/Risk | Costing Methods | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2007Modeling HPV and Cervical Cancer in the U.S. for Analyses of Screening and Vaccination
This paper discusses a model of human papillomavirus (HPV) and cervical cancer that incorporates uncertainty …
This paper discusses a model of human papillomavirus (HPV) and cervical cancer that incorporates uncertainty about the natural history of disease that was used to provide quantitative insight into U.S. policy choices for cervical cancer prevention. The authors developed a stochastic microsimulation of cervical cancer that distinguishes different HPV types by their incidence, clearance, persistence, and progression. For each set of sampled input parameters, likelihood-based goodness-of-fit (GOF) scores were computed based on comparisons between model-predicted…
Calibration/Validation | Science/Technology | Chronic Disease/Risk | Clinical Care | Microsimulation | Infectious Diseases | Health/Medicine | North America -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Decision Analysis | Economics/Finance | Science/Technology | Chronic Disease/Risk | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Global -
Resource PackWeb Portal, Teaching Resource 2023Resource Pack: Maternal Health Models and CEA
This resource pack, curated by the Center for Health Decision Science, provides selected examples of …
This resource pack, curated by the Center for Health Decision Science, provides selected examples of modeling approaches used to conduct analyses relevant to maternal and reproductive health. Some papers focus on a particular problem (e.g., screening for prenatal syphilis, comparison of alternative strategies for safe abortion), while others explore strategies for reducing morbidity and mortality from the entire spectrum of pregnancy and childbirth-related complications. Several of the examples model the primary drivers of maternal mortality (e.g.,…
Calibration/Validation | Science/Technology | Clinical Care | Costing Methods | Evidence Synthesis | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Health Systems | Health/Medicine | Global | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ToolInteractive 2020COVID-19 Antibody Tests: Calculator for Interpreting Test Results
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article …
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article below* on antibody testing for SARS-CoV-2 virus, allows users to vary the prior probability of infection, the sensitivity of SARS-CoV-2 antibody testing, and the specificity of SARS-CoV-2 antibody testing. Key points made in the article accompanying the interactive include: (1) antibody testing is likely to be most useful 2 weeks after infection, (2) sensitivity and specificity will vary over time and…
Technology Assessment | Science/Technology | Clinical Care | Probability/Bayes | Test Performance | Infectious Diseases | Health/Medicine